マツナガ　ユウタロウ   MATSUNAGA Yuutarou   松永　雄太郎    所属   医学部 医学科（東京女子医科大学病院）    職種   助教
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter retrospective study.
掲載誌名	正式名：Annals of gastroenterological surgery 略　 称：Ann Gastroenterol Surg ISSNコード：24750328/24750328
掲載区分	国内
巻・号・頁	9(4),pp.830-841
著者・共著者	YAMAMOTO Tomohisa,SHIMOKAWA Toshio,HAYASHI Masamichi,MIZUMA Masamichi,HIRANO Katsuhisa,OBA Atsushi,ASANO Toshimichi,MIYATO Hideyo,YOSHIDA Makoto,MATSUMOTO Ippei,KAWABATA Yasunari,SAKAMOTO Katsunori,MOTOI Fuyuhiko,ISHII Shigeto,HOMMA Yuki,MAEHIRA Hiromitsu,MATSUNAGA Yutaro,IKEMOTO Tetsuya,NAKAMURA MasafumiMATAKI, Yuko,NOTAKE Tsuyoshi,AKAHOSHI Keiichi,TAKAMI Hideki,YAMAKI So,HASHIMOTO Daisuke,KIMURA Yasutoshi,HIRANO Satoshi,INOUE Yosuke,FUJII Tsutomu,UNNO Michiaki,KODERA Yasuhiro,KITAYAMA Joji,SATOI Sohei
発行年月	2025/07
概要	BACKGROUND:The effectiveness of intraperitoneal chemotherapy using paclitaxel (i.p.-PTX) in pancreatic ductal adenocarcinoma (PDAC) patients with peritoneal dissemination remains elusive. The aim of this study is to investigate the clinical outcome of patients treated with i.p.-PTX combined with systemic chemotherapy compared with current standard chemotherapy including gemcitabine plus nab-paclitaxel and FOLFIRINOX.METHODS:Data of patients with peritoneal dissemination was retrospectively collected and analyzed (i.p.-PTX, n = 83; control, n = 86). Inverse probability of treatment-weighted analyses (IPTW) was used to balance baseline characteristics between two groups. Survival curves were estimated using Kaplan-Meier method, and the differences were compared using the log-rank test.RESULTS:No significant differences were noted in overall survival (14.9 vs. 15.5 months, p = 0.481) and progression free survival (9.5 vs. 9.1 months, p = 0.267) between i.p.-PTX and the control groups. Nevertheless, i.p.-PTX (9.9 months) significantly prolonged the median progression-free survival (PFS) time compared with the control (8.6 months), among the matched patients using IPTW (hazard ratio 0.666, p = 0.041). Moreover, subgroup analysis among the patients whose primary tumor were evaluated either as resectable or borderline resectable disease revealed significantly better overall survival in the i.p.-PTX group compared with the control group (21.3 vs. 14.7 months, hazard ratio; 0.532, p = 0.033). Conversion surgery was more frequently performed in the i.p.-PTX group than the control group (24% vs. 4%, p = 0.006).CONCLUSION:The i.p. PTX regimen prolonged PFS but not overall survival, and subgroup analysis suggested the possibility of survival benefit in patients with occult peritoneal dissemination whose primary tumor was classified as resectable/borderline resectable disease.
DOI	10.1002/ags3.70001
PMID	40607298